JP4405593B2 - チエノピリミジン類 - Google Patents

チエノピリミジン類 Download PDF

Info

Publication number
JP4405593B2
JP4405593B2 JP50934398A JP50934398A JP4405593B2 JP 4405593 B2 JP4405593 B2 JP 4405593B2 JP 50934398 A JP50934398 A JP 50934398A JP 50934398 A JP50934398 A JP 50934398A JP 4405593 B2 JP4405593 B2 JP 4405593B2
Authority
JP
Japan
Prior art keywords
pyrimidine
chloro
pyridin
reacting
thieno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP50934398A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000516223A5 (cg-RX-API-DMAC10.html
JP2000516223A (ja
Inventor
ローフス,ヨーナス
シェリング,ピエール
クルックセン,フランツ―ウェルナー
クリスタドラー,マリア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of JP2000516223A publication Critical patent/JP2000516223A/ja
Publication of JP2000516223A5 publication Critical patent/JP2000516223A5/ja
Application granted granted Critical
Publication of JP4405593B2 publication Critical patent/JP4405593B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP50934398A 1996-08-12 1997-07-30 チエノピリミジン類 Expired - Fee Related JP4405593B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19632423.8 1996-08-12
DE19632423A DE19632423A1 (de) 1996-08-12 1996-08-12 Thienopyrimidine
PCT/EP1997/004139 WO1998006722A1 (de) 1996-08-12 1997-07-30 Thienopyrimidine

Publications (3)

Publication Number Publication Date
JP2000516223A JP2000516223A (ja) 2000-12-05
JP2000516223A5 JP2000516223A5 (cg-RX-API-DMAC10.html) 2005-05-12
JP4405593B2 true JP4405593B2 (ja) 2010-01-27

Family

ID=7802392

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50934398A Expired - Fee Related JP4405593B2 (ja) 1996-08-12 1997-07-30 チエノピリミジン類

Country Status (28)

Country Link
US (1) US6110920A (cg-RX-API-DMAC10.html)
EP (1) EP0920431B1 (cg-RX-API-DMAC10.html)
JP (1) JP4405593B2 (cg-RX-API-DMAC10.html)
KR (1) KR100502271B1 (cg-RX-API-DMAC10.html)
CN (1) CN1081638C (cg-RX-API-DMAC10.html)
AR (1) AR009052A1 (cg-RX-API-DMAC10.html)
AT (1) ATE233265T1 (cg-RX-API-DMAC10.html)
AU (1) AU725227B2 (cg-RX-API-DMAC10.html)
BR (1) BR9711062A (cg-RX-API-DMAC10.html)
CA (1) CA2263561C (cg-RX-API-DMAC10.html)
CZ (1) CZ287772B6 (cg-RX-API-DMAC10.html)
DE (2) DE19632423A1 (cg-RX-API-DMAC10.html)
DK (1) DK0920431T3 (cg-RX-API-DMAC10.html)
ES (1) ES2191192T3 (cg-RX-API-DMAC10.html)
HU (1) HUP0001607A3 (cg-RX-API-DMAC10.html)
IL (1) IL128504A (cg-RX-API-DMAC10.html)
NO (1) NO990643D0 (cg-RX-API-DMAC10.html)
NZ (1) NZ334600A (cg-RX-API-DMAC10.html)
PL (1) PL190174B1 (cg-RX-API-DMAC10.html)
PT (1) PT920431E (cg-RX-API-DMAC10.html)
RU (1) RU2199541C2 (cg-RX-API-DMAC10.html)
SI (1) SI0920431T1 (cg-RX-API-DMAC10.html)
SK (1) SK282823B6 (cg-RX-API-DMAC10.html)
TR (1) TR199900308T2 (cg-RX-API-DMAC10.html)
TW (1) TW359672B (cg-RX-API-DMAC10.html)
UA (1) UA55421C2 (cg-RX-API-DMAC10.html)
WO (1) WO1998006722A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA977156B (cg-RX-API-DMAC10.html)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19819023A1 (de) * 1998-04-29 1999-11-04 Merck Patent Gmbh Thienopyrimidine
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
EP1323719A1 (en) 1999-03-30 2003-07-02 Nippon Soda Co., Ltd. Thienopyrimidine compounds and salts thereof and process for the preparation of the same
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
DE19950647A1 (de) * 1999-10-21 2001-04-26 Merck Patent Gmbh Imidazolderivate als Phosphodiesterase VII-Hemmer
DE10031585A1 (de) * 2000-06-29 2002-01-10 Merck Patent Gmbh 2-Aminoalkyl-thieno[2,3-d]pyrimidine
EP1329454A1 (en) * 2000-09-29 2003-07-23 Nippon Soda Co., Ltd. Thienopyrimidine compounds and their salts and process for preparation of both
WO2002062343A2 (en) * 2001-02-02 2002-08-15 Merck Patent Gmbh PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
JP2005503345A (ja) * 2001-04-30 2005-02-03 バイエル・コーポレーシヨン 新規な4−アミノ−5,6−置換チオフェノ[2,3−d]ピリミジン
HRP20040194A2 (en) * 2001-09-04 2004-08-31 Akzo Nobel Nv GLYCINE-SUBSTITUTED THIENO [2,3-d] PYRIMIDINES WITH COMBINED LH AND FSH AGONISTIC ACTIVITY
JPWO2003035653A1 (ja) * 2001-10-26 2005-02-10 日本曹達株式会社 ピリドチエノピリミジン化合物およびその塩
US7153412B2 (en) 2001-12-28 2006-12-26 Kabushiki Kaisha Toyota Chuo Kenkyusho Electrodes, electrochemical elements, gas sensors, and gas measurement methods
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
TW200410975A (en) * 2002-09-26 2004-07-01 Nihon Nohyaku Co Ltd New pesticide and method for using it, new substituted thienopyrimidine derivative, its intermediate, and method for producing it
GB0320300D0 (en) * 2003-08-29 2003-10-01 Cancer Rec Tech Ltd Pyrimidothiophene compounds
DE10351436A1 (de) * 2003-11-04 2005-06-09 Merck Patent Gmbh Verwendung von Thienopyrimidinen
GB0420719D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AR059898A1 (es) * 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
CA2696948C (en) * 2007-09-14 2013-04-30 Jose Maria Cid-Nunez 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones
EP2200985B1 (en) 2007-09-14 2011-07-13 Ortho-McNeil-Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
NZ584148A (en) * 2007-09-14 2011-05-27 Ortho Mcneil Janssen Pharm 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
CN101861316B (zh) * 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
US20100227853A1 (en) * 2008-04-18 2010-09-09 Trustees Of Boston College Inhibitors of cyclic amp phosphodiesterases
EP3085699B1 (en) 2008-07-31 2022-03-02 Firmenich Incorporated Processes for making sweet taste enhancers
CN102143955B (zh) 2008-09-02 2013-08-14 Omj制药公司 作为代谢型谷氨酸受体调节剂的3-氮杂二环[3.1.0]己烷衍生物
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2440001T3 (es) 2009-05-12 2014-01-27 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-A]piridina y su uso para el tratamiento o prevención de trastornos neurológicos y psiquiátricos
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
ES2552879T3 (es) 2010-11-08 2015-12-02 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN103946226A (zh) 2011-07-19 2014-07-23 无限药品股份有限公司 杂环化合物及其应用
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
JP6551936B2 (ja) 2012-08-06 2019-07-31 セノミックス インコーポレイテッドSenomyx, Inc. 甘味香味修飾因子
JO3155B1 (ar) 2013-02-19 2017-09-20 Senomyx Inc معدِّل نكهة حلوة
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
LT3431106T (lt) 2014-01-21 2021-02-10 Janssen Pharmaceutica Nv Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
EA033889B1 (ru) 2014-01-21 2019-12-05 Янссен Фармацевтика Нв Комбинация на основе лиганда sv2a и положительного аллостерического модулятора метаботропного глутаматергического рецептора 2 подтипа
MX2016014384A (es) 2014-06-23 2017-01-20 Celgene Corp Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado.
WO2017112777A1 (en) 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
KR102736865B1 (ko) 2017-06-21 2024-12-03 샤이 테라퓨틱스 엘엘씨 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물
MX2021001193A (es) 2018-08-07 2021-04-28 Firmenich Incorporated 2,2-dioxidos de 4-amino-1h-benzo[c][1,2,6]tiadiazina 5-sustituidos y formulaciones y usos de los mismos.
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
CN116178374B (zh) * 2023-01-13 2024-10-08 河北医科大学 小电导钙激活钾离子通道激动剂及其合成和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1570494A (en) * 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
ZA782648B (en) * 1977-05-23 1979-06-27 Ici Australia Ltd The prevention,control or eradication of infestations of ixodid ticks
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 4−アミノキナゾリン誘導体およびそれを含有する医薬品
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5869486A (en) * 1995-02-24 1999-02-09 Ono Pharmaceutical Co., Ltd. Fused pyrimidines and pyriazines as pharmaceutical compounds

Also Published As

Publication number Publication date
SK16499A3 (en) 1999-06-11
IL128504A0 (en) 2000-01-31
PT920431E (pt) 2003-07-31
PL190174B1 (pl) 2005-11-30
CN1081638C (zh) 2002-03-27
TR199900308T2 (xx) 1999-04-21
KR100502271B1 (ko) 2005-07-22
NO990643L (no) 1999-02-11
HUP0001607A3 (en) 2002-09-30
CN1227560A (zh) 1999-09-01
SI0920431T1 (en) 2003-08-31
DE19632423A1 (de) 1998-02-19
AU4203597A (en) 1998-03-06
HUP0001607A2 (hu) 2000-10-28
EP0920431B1 (de) 2003-02-26
ES2191192T3 (es) 2003-09-01
AR009052A1 (es) 2000-03-08
CZ287772B6 (en) 2001-01-17
US6110920A (en) 2000-08-29
IL128504A (en) 2003-01-12
DE59709404D1 (en) 2003-04-03
AU725227B2 (en) 2000-10-12
DK0920431T3 (da) 2003-06-02
EP0920431A1 (de) 1999-06-09
HK1021731A1 (en) 2000-06-30
WO1998006722A1 (de) 1998-02-19
KR20000029932A (ko) 2000-05-25
BR9711062A (pt) 1999-08-17
CA2263561A1 (en) 1998-02-19
SK282823B6 (sk) 2002-12-03
CA2263561C (en) 2007-02-20
ZA977156B (en) 1998-02-19
JP2000516223A (ja) 2000-12-05
NZ334600A (en) 2000-07-28
PL331538A1 (en) 1999-07-19
NO990643D0 (no) 1999-02-11
CZ44899A3 (cs) 1999-05-12
TW359672B (en) 1999-06-01
ATE233265T1 (de) 2003-03-15
RU2199541C2 (ru) 2003-02-27
UA55421C2 (uk) 2003-04-15

Similar Documents

Publication Publication Date Title
JP4405593B2 (ja) チエノピリミジン類
RU2197492C2 (ru) Тиенопиримидины с ингибирующим действием по отношению к фосфодиэстеразе v (pde v), способ их получения и фармацевтическая композиция
JP2004513966A (ja) チエノピリミジン類の使用
RU2224760C2 (ru) Конденсированные тиенопиримидины с ингибирующим фосфодиэстеразу V действием, способ их получения и фармацевтическая композиция
JP2003513973A (ja) ホスホジエステラーゼvii阻害剤としてのイミダゾピリジン誘導体
JP3870298B2 (ja) アミド誘導体
JP2003502429A (ja) ホスホジエステラーゼ阻害剤としてのチエノピリミジン
KR20040041166A (ko) 피리미딘 유도체
HUP0302515A2 (hu) Szulfamido-tienopirimidin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
JP2003512381A (ja) ホスホジエステラーゼvii阻害剤としてのイミダゾール誘導体
JP2004513963A (ja) ピラゾロ〔4,3−d〕ピリミジンの使用
JP2004517940A (ja) ピラゾロ[4,3−d]ピリミジンおよびニトレートまたはチエノピリミジンおよびニトレートを含む医薬製剤
JP4927299B2 (ja) チエノピリミジン
JP2003509511A (ja) アミン誘導体
MXPA99001387A (en) Thienopyrimidines
KR20020026011A (ko) 티에노피리미딘의 용도
HK1021731B (en) Thienopyrimidines
DE10104801A1 (de) Pharmazeutische Formulierungen enthaltend Thienopirimidine und Endothelin-Rezeptor-Antagonisten (2)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040730

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20040730

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080527

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080827

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080929

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20080929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090818

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20091006

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20091105

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121113

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees